HomeFile

File

View Category
Acute coronary syndromes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long...
solaci -
Learn More
Chronic Ischemic cardiopathy

Impact of FFR After Stenting: Useful or Mere Fun Fact?

Suboptimal fractional flow reserve (FFR) results after stenting only have a moderate impact on clinical hard points...
solaci -
Learn More
Antiplatelet

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after...
solaci -
Learn More
Coronary disease

Lower Mortality with Rechanneling vs. Medical Therapy

We had to wait for it, but we have finally seen a benefit in hard endpoints—such as...
solaci -
Learn More
Femoropopliteal

SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial...
solaci -
Learn More
Acute coronary syndromes

Biodegradable Polymer Myth Also Debunked for ACSs

During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs....
solaci -
Learn More
Other

Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However,...
solaci -
Learn More
Structural heart disease

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable...
solaci -
Learn More